All PlansCoverageMedium impact
Periureteral Bulking Agents as a Treatment of Vesicoureteral Reflux
Blue Cross & Blue Shield of Mississippi·MS · Urology, Pediatrics·Medical Policy
We identified it
Jun 20, 2026
Summary
New medical policy A.7.01.102 establishes coverage criteria for periureteral bulking agents (like Deflux, Vantris, Bulkamid) used to treat vesicoureteral reflux (VUR) in children. This outpatient endoscopic procedure is positioned as an alternative to open surgical repair or long-term antibiotic therapy.
Action Required
Immediately: Review complete policy A.7.01.102 at source URL to identify specific coverage criteria, prior authorization requirements, and billing guidelines for periureteral bulking agent procedures. Update billing team knowledge base with new coverage policy for VUR treatments including STING, HIT, and double HIT techniques.